Trial reportPloS one2013
Seroprevalence of mumps in The Netherlands: dynamics over a decade with high vaccination coverage and recent outbreaks.
Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Decade-long protection of the mumps vaccine: Insights from a large-scale serological study.PLoS neglected tropical diseases · 2025Article
- Seroprevalence for Measles, Varicella, Mumps and Rubella in the Trainee Obstetric Population: A Survey in Southern Italy.Vaccines · 2024Article
- Mumps serological surveillance following 10 years of a one-dose mumps-containing-vaccine policy in Fujian Province, China.Human vaccines & immunotherapeutics · 2022Article
- Current view on novel vaccine technologies to combat human infectious diseases.Applied microbiology and biotechnology · 2022Review
- Serostatus of IgG antibody against mumps virus in adult population of Al Madinah Al Munawarah, Saudi Arabia.Saudi medical journal · 2021Article
- Seroprevalence of Measles-, Mumps-, and Rubella-specific antibodies in the German adult population - cross-sectional analysis of the German Health Interview and Examination Survey for Adults (DEGS1).The Lancet regional health. Europe · 2021Article
- Novel mumps virus epitopes reveal robust cytotoxic T cell responses after natural infection but not after vaccination.Scientific reports · 2021Article
- Dynamics of the Antibody Response After a Third Dose of Measles-Mumps-Rubella Vaccine Indicate a Slower Decline Compared With a Second Dose.Open forum infectious diseases · 2020Article
- High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China.Human vaccines & immunotherapeutics · 2020Article
- Mumps Outbreaks in Vaccinated Populations-Is It Time to Re-assess the Clinical Efficacy of Vaccines?Frontiers in immunology · 2020Review
- Article
- Seroprevalence and Determinants Associated with Mumps Antibodies after 20 Years of MMR Vaccination in Urban Area of Shanghai, China.International journal of environmental research and public health · 2018Article
- Socioeconomic Status Is Associated With Antibody Levels Against Vaccine Preventable Diseases in the Netherlands.Frontiers in public health · 2018Article
- Mumps transmission in social networks: a cohort study.BMC infectious diseases · 2017Article
- Establishing a small animal model for evaluating protective immunity against mumps virus.PloS one · 2017Article
- Article
- Seroepidemiology of mumps in the general population of Jiangsu province, China after introduction of a one-dose measles-mumps-rubella vaccine.Scientific reports · 2015Article
- Dynamics of the serologic response in vaccinated and unvaccinated mumps cases during an epidemic.Human vaccines & immunotherapeutics · 2015Observational
- Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes.Expert review of vaccines · 2015Review
- Mumps serum antibody levels before and after an outbreak to assess infection and immunity in vaccinated students.Open forum infectious diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here we present mumps virus specific antibody levels in a large cross-sectional population-based serosurveillance study performed in the Netherlands in 2006/2007 (n = 7900). Results were compared with a similar study (1995/1996) and discussed in the light of recent outbreaks. Mumps antibodies were tested using a fluorescent bead-based multiplex immunoassay. Overall seroprevalence was 90.9% with higher levels in the naturally infected cohorts compared with vaccinated cohorts. Mumps virus vaccinations at 14 months and 9 years resulted in an increased seroprevalence and antibody concentration. The second vaccination seemed to be important in acquiring stable mumps antibody levels in the long term. In conclusion, the Dutch population is well protected against mumps virus infection. However, we identified specific age- and population groups at increased risk of mumps infection. Indeed, in 2007/2008 an outbreak has occurred in the low vaccination coverage groups emphasizing the predictive value of serosurveillance studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.